

**ASTRA TECH**

Astra Tech is engaged in the research, development, manufacture and marketing of medical devices and implants for use in healthcare, primarily in urology, surgery and odontology. It has a leading position in several countries in Europe and is expanding its operations in key markets, particularly in the US, Japan and South East Asia.

All product lines showed continued good sales growth in 2008. In pursuit of its growth strategy for Astra Tech Dental, the sales and marketing organisation for dental implants was further expanded during the year. Despite the downturn in the world economy, which negatively impacted business in the US, strong sales growth was achieved in major European countries as well as North America and Astra Tech increased its market share in the major markets. The economic slowdown is expected to continue to adversely impact demand in 2009.

In March 2008 a Regional Office for South East Asia was established in Malaysia, in order to provide an improved support and service to our customers in the region. Atlantis, which was acquired in 2007 and has provided Astra Tech with a new platform for development within digital dentistry is offering an important opportunity for continued growth for the dental implants product line. During the year a European manufacturing facility for Atlantis products was built at the company's headquarters site in Mölndal. Production started in October to supply all European markets.

The Astra Tech Training and Education Program has been further developed and in combination with its state-of-the-art Centre for Training and Education at its headquarters, advanced international education programmes and seminars are now being offered to existing and potential customers. Further investments have been made in R&D, clinical research and new production facilities to strengthen the product portfolio.

**APTIUM ONCOLOGY**

For more than 25 years, Aptium Oncology has been developing and managing hospital-based outpatient cancer centres in the US. Its distinctive and comprehensive approach to cancer care incorporates all outpatient oncology and ancillary services in a single facility for maximum patient comfort and convenience.

Ownership of Aptium Oncology gives us a unique window to the provider sector of the US oncology market and, through Aptium Oncology's network of over 160 physicians, access to many opinion leaders in the field of oncology who can help shape early phase drug development decisions. It is also involved in clinical trial delivery for a number of our pipeline products and provides scientific advice and staff training for oncology teams.

In 2008, Aptium Oncology continued to perform well in its cancer centre management business with positive profit and cash flow contributions. Focused on growth, Aptium Oncology continued to invest in sales and marketing. The resulting expansion of its consultancy business is creating new opportunities for management relationships in new markets in the US, with growing interest from international sources.

Clinical research is an integral part of care delivery at Aptium Oncology's affiliated cancer centres. In 2008, the company established the Aptium Oncology GI Cancer Consortium, bringing together eight leading US academic institutions that will collaborate to speed the process of finding and testing active new compounds for patients with gastrointestinal cancers.